ArticleGland surgery2026
Development and validation of a SEER-derived prognostic nomogram for non-metastatic Asian breast cancer patients.
Article in Gland surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer (BC) is the most prevalent cancer among American women. Asian Americans are confronting a rapidly increasing incidence, facing unique challenges within the healthcare system that contribute to disparities in cancer outcomes. This study aimed to develop and validate a prognostic nomogram for predicting long-term survival in Asian BC patients utilizing the Surveillance, Epidemiology, and End Results (SEER) database. Methods: Asian female BC patients diagnosed between 2000 and 2021 were identified from the SEER database. Following the application of inclusion and exclusion criteria, 38,269 patients were included and randomly divided into training (70%) and validation (30%) cohorts. Univariate and multivariate Cox regression analyses were conducted to identify independent prognostic factors, which were incorporated into a nomogram. The model's discriminative ability, calibration, and clinical utility were evaluated. Results: Independent predictors of overall survival included age, tumor grade, marital status, T stage, N stage, subtype, radiotherapy, and chemotherapy. The nomogram demonstrated strong discriminative performance, with concordance indices of 0.794 and 0.811 in the training and validation cohorts, respectively, demonstrating better discriminative performance than the traditional tumor-node-metastasis (TNM) staging system. Calibration plots and decision curve analysis confirmed excellent calibration and clinical applicability. Conclusions: This study presents a prognostic nomogram developed and validated exclusively in a large cohort of non-metastatic Asian American BC patients from the SEER database, incorporating modern molecular subtypes to improve prognostic stratification for this understudied population. By integrating readily available clinicopathological factors, the nomogram provides personalized survival forecasts, serving as a valuable tool for individualized management in this unique population. Further external validation and refinements are warranted to enhance its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.